Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

SGLT2 inhibitors, compared with GLP1 agonists, significantly lower risk for atrial fibrillation in patients with type 2 diabetes.

Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

Not all strokes are equally devastating, and new research shows that certain health risks don’t just increase your chances of ...

Boston Scientific, Medtronic, Abbott and J&J unveiled new data for their PFA devices in tandem with the Heart Rhythm ...

Abbott has reported new data from its Volt CE Mark Study in individuals treated with PFA therapy using the Volt PFA System ...

For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

“It was an experience that dramatically improved my life,” said Mike Prescott of Kenosha, who retired a couple of years ago ...

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...